Cargando…
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations
Monoclonal antibody-based targeted tumor therapy has greatly improved treatment options for patients. Antibodies against oncogenic receptor tyrosine kinases (RTKs), especially the ErbB receptor family, are prominent examples. However, long-term efficacy of such antibodies is limited by resistance me...
Autores principales: | Castoldi, Raffaella, Schanzer, Jürgen, Panke, Christian, Jucknischke, Ute, Neubert, Natalie J., Croasdale, Rebecca, Scheuer, Werner, Auer, Johannes, Klein, Christian, Niederfellner, Gerhard, Kobold, Sebastian, Sustmann, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036864/ https://www.ncbi.nlm.nih.gov/pubmed/27578890 http://dx.doi.org/10.1093/protein/gzw037 |
Ejemplares similares
-
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
por: Castoldi, R, et al.
Publicado: (2013) -
Molecular characterization of novel trispecific
ErbB-cMet-IGF1R antibodies and their
antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012) -
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
por: Metz, Silke, et al.
Publicado: (2012) -
P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model
por: Kobold, S, et al.
Publicado: (2014) -
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
por: Sustmann, Claudio, et al.
Publicado: (2019)